Harvard Pilgrim Health Care Home
  HPHConnect
 
  Learn more.
  Sign up for HPHConnect.
Medical Management
E-Transactions
HPHConnect
Pharmacy
For Your Patient
News Center
Network Matters
Newsletter Archives
Newsletter Registration
Newsroom
Office Support
Products
Provider Manual
Medicare Advantage
Research & Teaching
Resources & Links
 
Print    Text Size

Network Matters
News and Information for the
Harvard Pilgrim Health Care Network

February 2019

Retacrit Now Covered with Prior Authorization


Harvard Pilgrim now covers the medication Retacrit for members of our commercial plans. Retacrit is an epoetin alfa that was approved by the FDA in May 2018 as a biosimilar to Epogen and Procrit for the treatment of anemia due to: chronic kidney disease in patients on dialysis and not on dialysis; the use of zidovudine in patients with HIV infection; and the effects of concomitant myelosuppressive chemotherapy. It is also approved to reduce the need for allogeneic red blood cell transfusions in patients undergoing elective, noncardiac, nonvascular surgery.

As with Epogen and Procrit, the use of Retacrit requires prior authorization. You can find the complete list of covered indications and coverage criteria on Harvard Pilgrim’s updated Epogen, Procrit, and Retacrit prior authorization policy.

The following codes have been added for coverage, and require prior authorization:

  • Q5105 - Injection, epoetin alfa, biosimilar, (Retacrit) (for ESRD on dialysis), 100 units

  • Q5106 - Injection, epoetin alfa, biosimilar, (Retacrit) (for non-ESRD use), 1000 units

To request authorization, please contact CVS Health–NovoLogix via phone (844-387-1435) or fax (844-851-0882). For more information, please refer to Harvard Pilgrim’s Epogen, Procrit, and Retacrit Medical Review Criteria and prior authorization request form.

Email this article to a colleague   


Network Matters Archives

Download printer-friendly version

HPHCURRENT EVENTS

HPHConnect for Providers Updated with New Look and Functionality

2019 Physician Group Honor Roll Announced

CLINICIAN CORNER

Reminder: UM Decision-Making and Communications

Retacrit Now Covered with Prior Authorization

Harvard Pilgrim No Longer Covers Cooling Devices

Members’ Rights and Responsibilities

OFFICE ASSISTANT

Medicare Advantage: Report Primary Diagnosis Codes in Primary Position

2019 Fee Schedule Updates

PUBLICATION INFORMATION

Robert Farias,
Senior Vice President, Corporate Network Strategy

Annmarie Dadoly,
Editor

Joseph O'Riordan,
Writer

Kristin Edmonston,
Production Coordinator